| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 39 | 2024 | 356 | 9.230 |
Why?
|
| Drug Delivery Systems | 20 | 2023 | 225 | 6.970 |
Why?
|
| Interleukins | 31 | 2025 | 112 | 6.260 |
Why?
|
| Antineoplastic Agents | 22 | 2024 | 679 | 6.000 |
Why?
|
| Nanoparticles | 17 | 2020 | 287 | 5.680 |
Why?
|
| Exosomes | 10 | 2024 | 96 | 5.200 |
Why?
|
| Neoplasms | 20 | 2025 | 809 | 4.870 |
Why?
|
| RNA, Small Interfering | 14 | 2021 | 198 | 4.050 |
Why?
|
| Genetic Therapy | 24 | 2017 | 123 | 3.970 |
Why?
|
| ELAV-Like Protein 1 | 8 | 2021 | 30 | 3.710 |
Why?
|
| Cisplatin | 5 | 2020 | 179 | 2.140 |
Why?
|
| Apoptosis | 27 | 2021 | 775 | 2.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2017 | 105 | 2.060 |
Why?
|
| Cell Line, Tumor | 35 | 2021 | 1319 | 1.870 |
Why?
|
| Adenoviridae | 18 | 2010 | 67 | 1.780 |
Why?
|
| Immunotherapy | 5 | 2021 | 161 | 1.750 |
Why?
|
| Drug Carriers | 4 | 2023 | 115 | 1.650 |
Why?
|
| Humans | 83 | 2025 | 28097 | 1.620 |
Why?
|
| Nanomedicine | 5 | 2021 | 62 | 1.550 |
Why?
|
| Gene Transfer Techniques | 11 | 2017 | 67 | 1.440 |
Why?
|
| Cell Movement | 11 | 2017 | 373 | 1.430 |
Why?
|
| Dendrimers | 3 | 2020 | 15 | 1.380 |
Why?
|
| Ovarian Neoplasms | 5 | 2024 | 589 | 1.360 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 405 | 1.360 |
Why?
|
| Polymers | 3 | 2017 | 117 | 1.310 |
Why?
|
| Cell Proliferation | 15 | 2020 | 806 | 1.240 |
Why?
|
| Genes, Tumor Suppressor | 18 | 2021 | 39 | 1.240 |
Why?
|
| Chitosan | 3 | 2017 | 34 | 1.120 |
Why?
|
| Folate Receptor 1 | 2 | 2017 | 13 | 1.080 |
Why?
|
| MicroRNAs | 4 | 2021 | 301 | 1.070 |
Why?
|
| RNAi Therapeutics | 2 | 2016 | 13 | 1.050 |
Why?
|
| Animals | 34 | 2025 | 10423 | 1.000 |
Why?
|
| Doxorubicin | 2 | 2016 | 77 | 1.000 |
Why?
|
| Receptors, CXCR4 | 2 | 2015 | 29 | 0.950 |
Why?
|
| Liposomes | 5 | 2017 | 145 | 0.930 |
Why?
|
| DNA Damage | 7 | 2022 | 151 | 0.900 |
Why?
|
| Signal Transduction | 14 | 2021 | 1435 | 0.890 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 14 | 0.880 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 465 | 0.860 |
Why?
|
| DNA Helicases | 1 | 2024 | 52 | 0.860 |
Why?
|
| Magnetite Nanoparticles | 2 | 2014 | 16 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2016 | 155 | 0.810 |
Why?
|
| ErbB Receptors | 2 | 2014 | 100 | 0.800 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 178 | 0.780 |
Why?
|
| Liquid Biopsy | 2 | 2021 | 9 | 0.780 |
Why?
|
| Cell Survival | 10 | 2017 | 409 | 0.770 |
Why?
|
| Lipids | 2 | 2017 | 208 | 0.740 |
Why?
|
| Medical Oncology | 2 | 2021 | 94 | 0.720 |
Why?
|
| Lung Diseases | 1 | 2021 | 43 | 0.710 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 300 | 0.680 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2017 | 269 | 0.640 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 43 | 0.630 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2012 | 50 | 0.630 |
Why?
|
| Autophagy | 4 | 2017 | 73 | 0.610 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 215 | 0.610 |
Why?
|
| Heterocyclic Compounds | 2 | 2015 | 15 | 0.610 |
Why?
|
| Urinalysis | 1 | 2018 | 11 | 0.600 |
Why?
|
| Tumor Cells, Cultured | 10 | 2017 | 315 | 0.580 |
Why?
|
| Mice, Nude | 10 | 2017 | 331 | 0.570 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 10 | 0.570 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 25 | 0.560 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2017 | 55 | 0.560 |
Why?
|
| Gold | 2 | 2015 | 130 | 0.560 |
Why?
|
| Genetic Vectors | 8 | 2017 | 116 | 0.560 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 20 | 0.550 |
Why?
|
| Oncogenes | 1 | 2017 | 34 | 0.550 |
Why?
|
| Mice | 19 | 2016 | 4654 | 0.540 |
Why?
|
| Paclitaxel | 2 | 2017 | 190 | 0.530 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2015 | 102 | 0.530 |
Why?
|
| HMGA1a Protein | 1 | 2016 | 4 | 0.530 |
Why?
|
| Transgenes | 8 | 2010 | 63 | 0.520 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 189 | 0.520 |
Why?
|
| Molecular Targeted Therapy | 4 | 2024 | 135 | 0.500 |
Why?
|
| Nanotubes | 1 | 2015 | 15 | 0.490 |
Why?
|
| Cell Cycle | 7 | 2015 | 161 | 0.490 |
Why?
|
| Chemokine CXCL12 | 1 | 2015 | 9 | 0.480 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 130 | 0.470 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.460 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 68 | 0.450 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 190 | 0.450 |
Why?
|
| Technology, Pharmaceutical | 1 | 2014 | 9 | 0.440 |
Why?
|
| Female | 19 | 2024 | 15156 | 0.440 |
Why?
|
| Lactic Acid | 1 | 2014 | 92 | 0.430 |
Why?
|
| Receptors, Interleukin | 4 | 2006 | 12 | 0.390 |
Why?
|
| Prostatic Neoplasms | 2 | 2005 | 277 | 0.380 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 214 | 0.380 |
Why?
|
| Lung | 3 | 2016 | 379 | 0.380 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 7 | 0.380 |
Why?
|
| Cell Death | 5 | 2016 | 118 | 0.350 |
Why?
|
| Transfection | 2 | 2010 | 318 | 0.350 |
Why?
|
| Cholesterol | 3 | 2016 | 201 | 0.350 |
Why?
|
| Interleukin-10 | 4 | 2006 | 72 | 0.340 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2007 | 109 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 167 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 179 | 0.320 |
Why?
|
| Enzyme Activation | 3 | 2016 | 267 | 0.310 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 86 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 330 | 0.300 |
Why?
|
| Folic Acid | 2 | 2020 | 32 | 0.290 |
Why?
|
| DNA | 3 | 2008 | 374 | 0.290 |
Why?
|
| Genes, p53 | 1 | 2008 | 14 | 0.290 |
Why?
|
| Viral Vaccines | 1 | 2008 | 13 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 7 | 2006 | 149 | 0.290 |
Why?
|
| Quaternary Ammonium Compounds | 3 | 2012 | 18 | 0.290 |
Why?
|
| Fatty Acids, Monounsaturated | 3 | 2012 | 22 | 0.280 |
Why?
|
| Receptors, Virus | 1 | 2007 | 6 | 0.280 |
Why?
|
| Mice, Inbred BALB C | 6 | 2013 | 276 | 0.280 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2007 | 4 | 0.280 |
Why?
|
| Vitamin E | 1 | 2007 | 11 | 0.270 |
Why?
|
| Gene Silencing | 2 | 2017 | 65 | 0.270 |
Why?
|
| Capsid Proteins | 1 | 2007 | 12 | 0.270 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 145 | 0.260 |
Why?
|
| Receptors, Transferrin | 2 | 2017 | 18 | 0.260 |
Why?
|
| Caspase 9 | 2 | 2016 | 16 | 0.260 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 36 | 0.260 |
Why?
|
| Drug Liberation | 2 | 2016 | 29 | 0.260 |
Why?
|
| Cell Line | 5 | 2016 | 696 | 0.250 |
Why?
|
| NF-kappa B | 1 | 2007 | 191 | 0.250 |
Why?
|
| Doxycycline | 2 | 2016 | 19 | 0.250 |
Why?
|
| Genes, src | 1 | 2005 | 4 | 0.250 |
Why?
|
| Luciferases | 4 | 2010 | 49 | 0.240 |
Why?
|
| Benzylamines | 2 | 2015 | 19 | 0.240 |
Why?
|
| fas Receptor | 1 | 2005 | 19 | 0.240 |
Why?
|
| src-Family Kinases | 1 | 2005 | 71 | 0.240 |
Why?
|
| Sulindac | 1 | 2005 | 1 | 0.240 |
Why?
|
| Particle Size | 3 | 2014 | 101 | 0.240 |
Why?
|
| Kinetics | 2 | 2016 | 545 | 0.230 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 474 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2004 | 17 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 257 | 0.230 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 82 | 0.230 |
Why?
|
| Nanostructures | 1 | 2004 | 64 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 459 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 38 | 0.210 |
Why?
|
| Caffeine | 1 | 2003 | 39 | 0.210 |
Why?
|
| Cytokines | 6 | 2009 | 447 | 0.210 |
Why?
|
| Inflammation | 2 | 2004 | 636 | 0.210 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2017 | 32 | 0.200 |
Why?
|
| RNA, Messenger | 2 | 2015 | 659 | 0.200 |
Why?
|
| Plasmids | 4 | 2014 | 126 | 0.200 |
Why?
|
| Radiation Tolerance | 2 | 2020 | 28 | 0.200 |
Why?
|
| Down-Regulation | 3 | 2015 | 199 | 0.190 |
Why?
|
| Blotting, Western | 4 | 2015 | 514 | 0.190 |
Why?
|
| Melanoma | 5 | 2008 | 141 | 0.190 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 138 | 0.190 |
Why?
|
| Fibroblasts | 3 | 2016 | 157 | 0.190 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2021 | 26 | 0.180 |
Why?
|
| Caspases | 5 | 2017 | 43 | 0.180 |
Why?
|
| Trans-Activators | 5 | 2005 | 118 | 0.180 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 769 | 0.180 |
Why?
|
| Tumor Escape | 1 | 2021 | 11 | 0.180 |
Why?
|
| Time Factors | 5 | 2007 | 1592 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 25 | 0.180 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 33 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 60 | 0.180 |
Why?
|
| Immunity | 1 | 2021 | 26 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 79 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 107 | 0.170 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2020 | 7 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2005 | 135 | 0.170 |
Why?
|
| Drug Synergism | 2 | 2015 | 104 | 0.170 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 16 | 0.170 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2020 | 6 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 80 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2021 | 193 | 0.160 |
Why?
|
| Cell Division | 4 | 2003 | 154 | 0.160 |
Why?
|
| Workflow | 1 | 2020 | 25 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2020 | 82 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 107 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 58 | 0.150 |
Why?
|
| Gene Expression | 2 | 2015 | 417 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2020 | 97 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 156 | 0.150 |
Why?
|
| HeLa Cells | 1 | 2019 | 208 | 0.150 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 285 | 0.150 |
Why?
|
| A549 Cells | 1 | 2017 | 17 | 0.140 |
Why?
|
| Mitochondria | 3 | 2017 | 369 | 0.140 |
Why?
|
| G1 Phase | 1 | 2017 | 17 | 0.140 |
Why?
|
| Static Electricity | 1 | 2017 | 35 | 0.140 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 30 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 328 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 114 | 0.140 |
Why?
|
| Neoplasm Transplantation | 4 | 2009 | 90 | 0.130 |
Why?
|
| Tissue Distribution | 1 | 2017 | 137 | 0.130 |
Why?
|
| Muscle Cells | 1 | 2016 | 15 | 0.130 |
Why?
|
| RNA Interference | 1 | 2017 | 137 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 134 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2017 | 34 | 0.130 |
Why?
|
| Ligands | 1 | 2017 | 176 | 0.130 |
Why?
|
| Biomarkers | 3 | 2010 | 765 | 0.130 |
Why?
|
| Transferrin | 1 | 2015 | 10 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 34 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2016 | 152 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2015 | 578 | 0.120 |
Why?
|
| Surface Plasmon Resonance | 1 | 2015 | 37 | 0.120 |
Why?
|
| Endocytosis | 1 | 2015 | 89 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 68 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 267 | 0.120 |
Why?
|
| Mice, Inbred C3H | 3 | 2004 | 74 | 0.120 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2007 | 13 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 133 | 0.120 |
Why?
|
| Bystander Effect | 2 | 2005 | 16 | 0.120 |
Why?
|
| Models, Biological | 3 | 2008 | 466 | 0.120 |
Why?
|
| Fluorescamine | 1 | 2014 | 2 | 0.110 |
Why?
|
| Carbon | 1 | 2015 | 108 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 34 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 83 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 607 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 463 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 68 | 0.110 |
Why?
|
| Polyesters | 1 | 2014 | 35 | 0.110 |
Why?
|
| Flow Cytometry | 5 | 2008 | 289 | 0.110 |
Why?
|
| Immunoblotting | 2 | 2005 | 124 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 27 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 298 | 0.110 |
Why?
|
| Cell Differentiation | 4 | 2003 | 407 | 0.110 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2013 | 21 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 71 | 0.110 |
Why?
|
| Phototherapy | 1 | 2013 | 28 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 30 | 0.100 |
Why?
|
| Contrast Media | 1 | 2014 | 96 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 140 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2003 | 60 | 0.100 |
Why?
|
| Nanotubes, Carbon | 1 | 2013 | 50 | 0.100 |
Why?
|
| Mebendazole | 2 | 2002 | 10 | 0.100 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 325 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 524 | 0.090 |
Why?
|
| Radiation, Ionizing | 2 | 2016 | 25 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 123 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 490 | 0.090 |
Why?
|
| Annexin A5 | 2 | 2013 | 24 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 3 | 2005 | 42 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 7 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2008 | 15 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 21 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 113 | 0.070 |
Why?
|
| Tocopherols | 1 | 2007 | 3 | 0.070 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2007 | 8 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 11 | 0.070 |
Why?
|
| Enterovirus | 1 | 2007 | 10 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2007 | 62 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2007 | 58 | 0.070 |
Why?
|
| Mitochondrial Membranes | 1 | 2007 | 20 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 144 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 103 | 0.070 |
Why?
|
| G2 Phase | 2 | 2003 | 15 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2003 | 29 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 2 | 2004 | 97 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2007 | 103 | 0.060 |
Why?
|
| Male | 4 | 2005 | 13491 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 144 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2002 | 43 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 68 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 7 | 0.060 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2004 | 1 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 27 | 0.060 |
Why?
|
| Naproxen | 1 | 2004 | 14 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2004 | 42 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 66 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2004 | 2 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2004 | 8 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2004 | 68 | 0.060 |
Why?
|
| Gelatin | 1 | 2004 | 11 | 0.060 |
Why?
|
| Fibrosarcoma | 1 | 2004 | 12 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2004 | 40 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 391 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 36 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 54 | 0.050 |
Why?
|
| Endostatins | 1 | 2003 | 3 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 128 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2003 | 12 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 97 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2003 | 22 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 343 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 162 | 0.050 |
Why?
|
| Chemokines | 1 | 2003 | 74 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 199 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 58 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 65 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 67 | 0.050 |
Why?
|
| Pinocytosis | 1 | 2003 | 17 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 95 | 0.050 |
Why?
|
| Antinematodal Agents | 1 | 2002 | 3 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2003 | 107 | 0.050 |
Why?
|
| Mitosis | 1 | 2003 | 114 | 0.050 |
Why?
|
| Tubulin | 1 | 2002 | 31 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2022 | 632 | 0.050 |
Why?
|
| Colon | 1 | 2003 | 121 | 0.050 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 4 | 0.050 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 5 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 3 | 2013 | 163 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 18 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2003 | 80 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2002 | 52 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 33 | 0.050 |
Why?
|
| Collagen | 1 | 2003 | 156 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 48 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2003 | 202 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 110 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 247 | 0.040 |
Why?
|
| beta Catenin | 3 | 2005 | 66 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 540 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Research | 1 | 2019 | 92 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 6 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2017 | 34 | 0.030 |
Why?
|
| Comet Assay | 1 | 2016 | 5 | 0.030 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2016 | 14 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2013 | 352 | 0.030 |
Why?
|
| Optical Devices | 1 | 2015 | 3 | 0.030 |
Why?
|
| Refractometry | 1 | 2015 | 6 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 2 | 2007 | 80 | 0.030 |
Why?
|
| Adsorption | 1 | 2015 | 32 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2015 | 19 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 25 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 119 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 89 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2015 | 66 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 217 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 230 | 0.030 |
Why?
|
| Suspensions | 1 | 2013 | 6 | 0.030 |
Why?
|
| Maleimides | 1 | 2013 | 6 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2013 | 17 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 20 | 0.030 |
Why?
|
| Biotinylation | 1 | 2013 | 19 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 2013 | 26 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 69 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 194 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2013 | 74 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 101 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 31 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 413 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 668 | 0.020 |
Why?
|
| Disease Progression | 2 | 2004 | 473 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 99 | 0.020 |
Why?
|
| Triptorelin Pamoate | 1 | 2009 | 1 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2009 | 22 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 453 | 0.020 |
Why?
|
| Disulfides | 1 | 2009 | 34 | 0.020 |
Why?
|
| Glycosylation | 1 | 2009 | 70 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 73 | 0.020 |
Why?
|
| Cysteine | 1 | 2009 | 68 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 97 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 208 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 257 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 103 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2005 | 4 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2005 | 34 | 0.010 |
Why?
|
| Injections | 1 | 2005 | 31 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 17 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 2004 | 29 | 0.010 |
Why?
|
| Virus Replication | 1 | 2005 | 65 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2004 | 25 | 0.010 |
Why?
|
| Caspase 12 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Tunicamycin | 1 | 2004 | 3 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Brefeldin A | 1 | 2004 | 5 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 23 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 2004 | 11 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 21 | 0.010 |
Why?
|
| Protein Folding | 1 | 2004 | 47 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 55 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 38 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 49 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 39 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 125 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 2003 | 15 | 0.010 |
Why?
|
| Cadherins | 1 | 2003 | 24 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 478 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 76 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 138 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 10 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2002 | 5 | 0.010 |
Why?
|
| Endothelium | 1 | 2002 | 28 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 189 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 187 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 252 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 658 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 2379 | 0.010 |
Why?
|